Pulmatrix

PULM · Nasdaq · United States

Share price · PULM

$1.34-0.21 (-13.55%) 3M

close as of 2026-11-18 · 24h delayed · vol 6K (0.2x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when PULM's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 4 Nov 2026+14.3%
  2. 22 Oct 2026-9.6%

    Nothing announced by PULM that day or the session before.

  3. 21 Oct 2026+9.8%

    Nothing announced by PULM that day or the session before.

  4. 21 Sep 2026+16.7%

    Nothing announced by PULM that day or the session before.

  5. 9 Sep 2026+6.1%
  6. 8 Jul 2026+8.7%

    Nothing announced by PULM that day or the session before.

  7. 25 Jun 2026+9.2%
  8. 26 Mar 2026-28.8%
  9. 20 Mar 2026+15.8%

    Nothing announced by PULM that day or the session before.

  10. 2 Mar 2026-36.8%

Share of unusual movement by asset

For each asset, the share of PULM's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Itraconazole (PUR1900)
events and moves
1shown from 8 days
Assets with fewer than 8 event days, together—0%
Other company news (earnings, financing, releases naming no asset)—49%
Sessions with no dated event—51%

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
2Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 2
fungal CYP51 (lanosterol 14α-demethylase)Small molecule
Allergic Bronchopulmonary Aspergillosis
PUR1800No recent activity
Phase 1
Narrow-spectrum kinase (p38/Syk-family)Small molecule
Chronic Obstructive Pulmonary Disease

Upcoming events

No upcoming trial completions or earnings dates on record for this company's assets.

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

13 August 2026Topline resultItraconazole (PUR1900)Cipla completed its Phase 2 of inhaled itraconazole (PUR1900) in India with positive results; India's CDSCO approved a Phase 3
Cipla · Source ↗

Financial reports

Quarterly & interim (15)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2—$0$2.2M$1.0M-$1.1M operating cash flowreport ↗
View 14 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q1—$0$3.3M$1.2M-$1.1M operating cash flowreport ↗
2025-Q3—<$0.1M$4.8M$0.9M-$1.0M operating cash flowreport ↗
2025-Q2—<$0.1M$5.8M$1.6M-$1.9M operating cash flowreport ↗
2025-Q1—<$0.1M$7.7M$1.8M-$1.8M operating cash flowreport ↗
2024-Q3$0.4M$0.8M$11M$2.6M-$3.1M operating cash flowreport ↗
2024-Q2$1.6M$2.8M$12M$5.8M-$3.7M operating cash flowreport ↗
2024-Q1$5.9M$3.5M$16M—-$2.7M operating cash flowreport ↗
2023-Q3$1.8M$4.0M$21M$3.8M-$4.1M operating cash flowreport ↗
2023-Q2$1.8M$4.2M$26M$3.8M-$4.9M operating cash flowreport ↗
2023-Q1$1.5M$3.9M$31M$4.5M-$4.9M operating cash flowreport ↗
2022-Q3$1.9M$5.3M$41M$5.0M-$3.6M operating cash flowreport ↗
2022-Q2$1.3M$4.3M$43M$4.6M-$4.6M operating cash flowreport ↗
2022-Q1$1.2M$4.2M$48M$5.0M-$6.1M operating cash flowreport ↗
2021-Q3$1.1M$4.0M$53M$8.2M-$3.3M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY—<$0.1M$4.1M$1.3M-$5.4M operating cash flowreport ↗

Pulmatrix reported revenue of nil for fiscal 2025, versus $7.81M in 2024, with the 2024 revenue primarily tied to the Cipla PUR1900 agreement. R&D spend was $0.04M, down 99.4% YoY, and cash and equivalents were $4.09M as of December 31, 2025. The company recorded a net loss of $5.16M.

Management said the current cash position is expected to fund operations into the first quarter of 2027. The company continues to pursue its proposed merger with Cullgen, with CSRC approval among remaining closing conditions, and both parties have waived the No Solicitation clause to explore alternative transactions. Pulmatrix is also seeking to license or monetize its iSPERSE technology and related clinical programs, including Phase 2-ready PUR3100 for acute migraine, PUR1800 for AECOPD, and PUR1900, which its partner Cipla has been approved to advance to Phase 3 in India.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$7.8M$7.2M$9.5M$2.4M-$11M operating cash flowreport ↗
2023-FY$7.3M$16M$19M$3.5M-$16M operating cash flowreport ↗
2022-FY$6.1M$18M$36M$4.7M-$19M operating cash flowreport ↗
2021-FY$5.2M$15M$54M$5.0M-$20M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases (—), 0 sales (—). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-02-03Higgins Michael J · directorAward / grant (derivative)8,800——Form 4
2023-01-26Batycky Richard P. · directorAward / grant (derivative)1,700——Form 4
2023-01-26Varadan Anand · directorAward / grant (derivative)1,700——Form 4
2023-01-26Cabell Christopher · directorAward / grant (derivative)1,700——Form 4
2023-01-26Higgins Michael J · directorAward / grant (derivative)2,436——Form 4
2023-01-26Bazemore Todd · directorAward / grant (derivative)1,700——Form 4
2023-01-26Raad Teofilo David · director, Chief Executive OfficerAward / grant (derivative)34,900——Form 4
2023-01-26Wasilewski Margaret · Chief Medical OfficerAward / grant (derivative)11,400——Form 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 15 reporting institutions held 0.3M shares ($425K, 9.0% of shares outstanding).

#InstitutionSharesValue
1RENAISSANCE TECHNOLOGIES LLC109,148$141K
2BlackRock, Inc.54,899$71K
3GEODE CAPITAL MANAGEMENT, LLC44,629$58K
4VANGUARD CAPITAL MANAGEMENT LLC33,594$43K
5SBI Securities Co., Ltd.30,085$39K
6VANGUARD FIDUCIARY TRUST CO14,715$19K
7JANE STREET GROUP, LLC14,584$19K
8STATE STREET CORP13,945$18K
9XTX Topco Ltd13,669$18K
10Tower Research Capital LLC (TRC)207$267
11UBS Group AG23$30
12Farther Finance Advisors, LLC7$9
13Allworth Financial LP3$4
14NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO1$1
15ROYAL BANK OF CANADA7$0